nach oben

Calcified Tissue International

Erschienen in:

01.07.2012 | Original Research

Targeted Disruption of TGFBI in Mice Reveals Its Role in Regulating Bone Mass and Bone Size through Periosteal Bone Formation

verfasst von: Hongrun Yu, Jon E. Wergedal, Yongliang Zhao, Subburaman Mohan

Erschienen in: Calcified Tissue International | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Transforming growth factor-beta induced (TGFBI) and periostin are two closely related proteins in structure as well as in function. A previous study found that periostin positively regulates bone size. Here, we hypothesize that TGFBI has a similar function in bone development. To test this hypothesis, we employed TGFBI-deficient mice, which were generated by targeted disruption of the TGFBI gene. We bred these mice with C57BL/6J mice to generate homozygous TGFBI-deficient (TGFBI^−/−) mice and homozygous wild-type littermates. All mice were raised to 12 weeks of age. Bone mass parameters were determined by PIXImus and micro-CT, bone strength parameters by three-point bending, and bone formation and resorption parameters by histomorphometry. We found that targeted disruption of TGFBI led to reduced body size, bone mass, bone size, and bone strength. This indicates that, like periostin, TGFBI also positively regulates bone size and that changes in bone size affect bone strength. Furthermore, there was also a significant decrease in periosteal, but not endosteal, bone formation rate of cortical bone in TGFBI^−/− mice, suggesting that the observed effect of TGFBI on bone mass and bone size was largely caused by the effect of TGFBI on periosteal bone formation.

Wergedal JE, Sheng MH, Ackert-Bicknell CL, Beamer WG, Baylink DJ (2005) Genetic variation in femur extrinsic strength in 29 different inbred strains of mice is dependent on variations in femur cross-sectional geometry and bone density. Bone 36:111–122PubMedCrossRef

Takeshita S, Kikuno R, Tezuka K, Amann E (1993) Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294(Pt 1):271–278PubMed

Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14:1239–1249PubMedCrossRef

Kashima TG, Nishiyama T, Shimazu K, Shimazaki M, Kii I, Grigoriadis AE, Fukayama M, Kudo A (2009) Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol 40:226–237PubMedCrossRef

Kii I, Amizuka N, Minqi L, Kitajima S, Saga Y, Kudo A (2006) Periostin is an extracellular matrix protein required for eruption of incisors in mice. Biochem Biophys Res Commun 342:766–772PubMedCrossRef

Ma D, Zhang R, Sun Y, Rios HF, Haruyama N, Han X, Kulkarni AB, Qin C, Feng JQ (2011) A novel role of periostin in postnatal tooth formation and mineralization. J Biol Chem 286:4302–4309PubMedCrossRef

Rios H, Koushik SV, Wang H, Wang J, Zhou HM, Lindsley A, Rogers R, Chen Z, Maeda M, Kruzynska-Frejtag A, Feng JQ, Conway SJ (2005) Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25:11131–11144PubMedCrossRef

Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF (1992) cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 11:511–522PubMedCrossRef

LeBaron RG, Bezverkov KI, Zimber MP, Pavelec R, Skonier J, Purchio AF (1995) Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. J Invest Dermatol 104:844–849PubMedCrossRef

10.

Skonier J, Bennett K, Rothwell V, Kosowski S, Plowman G, Wallace P, Edelhoff S, Disteche C, Neubauer M, Marquardt H et al (1994) beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 13:571–584PubMedCrossRef

11.

Thapa N, Lee BH, Kim IS (2007) TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol 39:2183–2194PubMedCrossRef

12.

Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, Subramaniam M, Spelsberg TC, Oursler MJ (2011) TGF-beta inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One 6:e17522PubMedCrossRef

13.

Runager K, Basaiawmoit RV, Deva T, Andreasen M, Valnickova Z, Sorensen CS, Karring H, Thogersen IB, Christiansen G, Underhaug J, Kristensen T, Nielsen NC, Klintworth GK, Otzen DE, Enghild JJ (2008) Human phenotypically distinct TGFBI corneal dystrophies are linked to the stability of the fourth FAS1 domain of TGFBIp. J Biol Chem 286:4951–4958CrossRef

14.

Ferguson JW, Thoma BS, Mikesh MF, Kramer RH, Bennett KL, Purchio A, Bellard BJ, LeBaron RG (2003) The extracellular matrix protein betaIG-H3 is expressed at myotendinous junctions and supports muscle cell adhesion. Cell Tissue Res 313:93–105PubMedCrossRef

15.

Jung MY, Thapa N, Kim JE, Yang JD, Cho BC, Kim IS (2007) Recombinant tetra-cell adhesion motifs supports adhesion, migration and proliferation of keratinocytes/fibroblasts, and promotes wound healing. Exp Mol Med 39:663–672PubMed

16.

Kim JE, Jeong HW, Nam JO, Lee BH, Choi JY, Park RW, Park JY, Kim IS (2002) Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem 277:46159–46165PubMedCrossRef

17.

Kim JE, Kim EH, Han EH, Park RW, Park IH, Jun SH, Kim JC, Young MF, Kim IS (2000) A TGF-beta-inducible cell adhesion molecule, betaig-h3, is downregulated in melorheostosis and involved in osteogenesis. J Cell Biochem 77:169–178PubMedCrossRef

18.

Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS (2000) Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem 275:30907–30915PubMedCrossRef

19.

Kim JE, Park RW, Choi JY, Bae YC, Kim KS, Joo CK, Kim IS (2002) Molecular properties of wild-type and mutant betaIG-H3 proteins. Invest Ophthalmol Vis Sci 43:656–661PubMed

20.

Nam JO, Kim JE, Jeong HW, Lee SJ, Lee BH, Choi JY, Park RW, Park JY, Kim IS (2003) Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem 278:25902–25909PubMedCrossRef

21.

Schorderet DF, Menasche M, Morand S, Bonnel S, Buchillier V, Marchant D, Auderset K, Bonny C, Abitbol M, Munier FL (2000) Genomic characterization and embryonic expression of the mouse Bigh3 (Tgfbi) gene. Biochem Biophys Res Commun 274:267–274PubMedCrossRef

22.

Becker J, Erdlenbruch B, Noskova I, Schramm A, Aumailley M, Schorderet DF, Schweigerer L (2006) Keratoepithelin suppresses the progression of experimental human neuroblastomas. Cancer Res 66:5314–5321PubMedCrossRef

23.

Calaf GM, Echiburu-Chau C, Zhao YL, Hei TK (2008) BigH3 protein expression as a marker for breast cancer. Int J Mol Med 21:561–568PubMed

24.

Genini M, Schwalbe P, Scholl FA, Schafer BW (1996) Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 66:571–577PubMedCrossRef

25.

Guo YS, Tang J, Chen B, Huang W, Li Y, Cui HY, Zhang X, Wang SJ, Chen ZN, Jiang J (2011) betaig-h3 regulates store-operated Ca²⁺ entry and promotes the invasion of human hepatocellular carcinoma cells. Cell Biol Int 35:811–817PubMedCrossRef

26.

Yamanaka M, Kimura F, Kagata Y, Kondoh N, Asano T, Yamamoto M, Hayakawa M (2008) BIGH3 is overexpressed in clear cell renal cell carcinoma. Oncol Rep 19:865–874PubMed

27.

Zamilpa R, Rupaimoole R, Phelix CF, Somaraki-Cormier M, Haskins W, Asmis R, LeBaron RG (2009) C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells. Matrix Biol 28:347–353PubMedCrossRef

28.

Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, Balajee AS, Bhagat G, Hei TK, Zhao Y (2009) TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res 69:37–44PubMedCrossRef

29.

Zhao Y, El-Gabry M, Hei TK (2006) Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 45:84–92PubMedCrossRef

30.

Zhao YL, Piao CQ, Hei TK (2002) Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21:7471–7477PubMedCrossRef

31.

Kim BY, Olzmann JA, Choi SI, Ahn SY, Kim TI, Cho HS, Suh H, Kim EK (2009) Corneal dystrophy-associated R124H mutation disrupts TGFBI interaction with periostin and causes mislocalization to the lysosome. J Biol Chem 284:19580–19591PubMedCrossRef

32.

Paliwal P, Sharma A, Tandon R, Sharma N, Titiyal JS, Sen S, Kaur P, Dube D, Vajpayee RB (2010) TGFBI mutation screening and genotype–phenotype correlation in north Indian patients with corneal dystrophies. Mol Vis 16:1429–1438PubMed

33.

Park SJ, Park S, Ahn HC, Kim IS, Lee BJ (2004) Conformational resemblance between the structures of integrin-activating pentapeptides derived from betaig-h3 and RGD peptide analogues in a membrane environment. Peptides 25:199–205PubMedCrossRef

34.

Rawe IM, Zhan Q, Burrows R, Bennett K, Cintron C (1997) Beta-ig: molecular cloning and in situ hybridization in corneal tissues. Invest Ophthalmol Vis Sci 38:893–900PubMed

35.

Yun SJ, Kim MO, Kim SO, Park J, Kwon YK, Kim IS, Lee EH (2002) Induction of TGF-beta-inducible gene-h3 (betaig-h3) by TGF-beta1 in astrocytes: implications for astrocyte response to brain injury. Brain Res Mol Brain Res 107:57–64PubMedCrossRef

36.

Ohno S, Doi T, Tsutsumi S, Okada Y, Yoneno K, Kato Y, Tanne K (2002) RGD-CAP (βig-h3) is expressed in precartilage condensation and in prehypertrophic chondrocytes during cartilage development. Biochim Biophys Acta 1572:114–122PubMedCrossRef

37.

Thapa N, Kang KB, Kim IS (2005) Beta ig-h3 mediates osteoblast adhesion and inhibits differentiation. Bone 36:232–242PubMedCrossRef

38.

Hoersch S, Andrade-Navarro MA (2010) Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evol Biol 10:30PubMedCrossRef

39.

Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339PubMedCrossRef

40.

Yoshioka N, Fuji S, Shimakage M, Kodama K, Hakura A, Yutsudo M, Inoue H, Nojima H (2002) Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene. Exp Cell Res 279:91–99PubMedCrossRef

41.

Masinde GL, Li X, Gu W, Wergedal J, Mohan S, Baylink DJ (2002) Quantitative trait loci for bone density in mice: the genes determining total skeletal density and femur density show little overlap in F2 mice. Calcif Tissue Int 71:421–428PubMedCrossRef

42.

Kesavan C, Mohan S (2010) Bone mass gained in response to external loading is preserved for several weeks following cessation of loading in 10 week C57BL/6J mice. J Musculoskelet Neuronal Interact 10:274–280PubMed

43.

Wergedal JE, Sheng MH, Ackert-Bicknell CL, Beamer WG, Baylink DJ (2002) Mouse genetic model for bone strength and size phenotypes: NZB/B1NJ and RF/J inbred strains. Bone 31:670–674PubMedCrossRef

44.

Sheng MH, Lau KH, Beamer WG, Baylink DJ, Wergedal JE (2004) In vivo and in vitro evidence that the high osteoblastic activity in C3H/HeJ mice compared to C57BL/6J mice is intrinsic to bone cells. Bone 35:711–719PubMedCrossRef

45.

Ohno S, Doi T, Fujimoto K, Ijuin C, Tanaka N, Tanimoto K, Honda K, Nakahara M, Kato Y, Tanne K (2002) RGD-CAP (betaig-h3) exerts a negative regulatory function on mineralization in the human periodontal ligament. J Dent Res 81:822–825PubMedCrossRef

46.

Ohno S, Tanaka N, Ueki M, Honda K, Tanimoto K, Yoneno K, Ohno-Nakahara M, Fujimoto K, Kato Y, Tanne K (2005) Mechanical regulation of terminal chondrocyte differentiation via RGD-CAP/beta ig-h3 induced by TGF-beta. Connect Tissue Res 46:227–234PubMedCrossRef

47.

Han MS, Kim JE, Shin HI, Kim IS (2008) Expression patterns of betaig-h3 in chondrocyte differentiation during endochondral ossification. Exp Mol Med 40:453–460PubMedCrossRef

48.

Dieudonne SC, Kerr JM, Xu T, Sommer B, DeRubeis AR, Kuznetsov SA, Kim IS, Gehron Robey P, Young MF (1999) Differential display of human marrow stromal cells reveals unique mRNA expression patterns in response to dexamethasone. J Cell Biochem 76:231–243PubMedCrossRef

49.

Merle B, Garnero P (2012) The multiple facets of periostin in bone metabolism. Osteoporos Int 23:1199–1212PubMedCrossRef

50.

Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757–765PubMedCrossRef

Titel: Targeted Disruption of TGFBI in Mice Reveals Its Role in Regulating Bone Mass and Bone Size through Periosteal Bone Formation
verfasst von: Hongrun Yu
Jon E. Wergedal
Yongliang Zhao
Subburaman Mohan
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 1/2012
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-012-9613-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Targeted Disruption of TGFBI in Mice Reveals Its Role in Regulating Bone Mass and Bone Size through Periosteal Bone Formation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Potential Impact of Benzodiazepine Use on the Rate of Hip Fractures in Five Large European Countries and the United States

Dietary Patterns in Relation to Bone Mineral Density Among Menopausal Iranian Women

Cathepsin K Preferentially Solubilizes Matured Bone Matrix

Endogenous Estradiol and The Risk of Incident Fracture in Postmenopausal Women: The OPUS Study

Early Response of Bone Marrow Osteoprogenitors to Skeletal Unloading and Sclerostin Antibody

The Effect of Care Pathways for Hip Fractures: A Systematic Review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin